New gene sites affecting nonalcoholic fatty liver disease discovered<\/a><\/h3>NAFLD is a condition where fat accumulates in the liver (steatosis) and can lead to liver inflammation (nonalcoholic steatohepatitis or NASH) and permanent liver damage (fibrosis\/cirrhosis). NAFLD affects anywhere from 11% to 45% of some populations and is associated with obesity, hypertension, and problems regulating serum lipids or glucose.<\/summary><\/li>IL28B gene predicts treatment outcome for liver transplantation patients<\/a><\/h3>German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV).<\/summary><\/li>Redesign of US donor-liver network could boost transplants by several hundred per year<\/a><\/h3>A redesign of the nation\u00e2\u20ac\u2122s donor-liver distribution network developed by University of Pittsburgh researchers could result in several hundred more people each year receiving the transplants they need.<\/summary><\/li>Nanotechnology may lead to new treatment of liver cancer<\/a><\/h3>Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.<\/summary><\/li>The 'death switch' in sepsis also promotes survival<\/a><\/h3>Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis.<\/summary><\/li>Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>![\"Cell](\"https:\/\/d.medicaldaily.com\/en\/full\/220882\/cell-transplantation-reports-success-treating-end-stage-liver-disease.jpg?w=466&h=311&f=567f8bace9434f91eb39e259e6bff3ca\")
<\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
IL28B gene predicts treatment outcome for liver transplantation patients<\/a><\/h3>German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV).<\/summary><\/li>Redesign of US donor-liver network could boost transplants by several hundred per year<\/a><\/h3>A redesign of the nation\u00e2\u20ac\u2122s donor-liver distribution network developed by University of Pittsburgh researchers could result in several hundred more people each year receiving the transplants they need.<\/summary><\/li>Nanotechnology may lead to new treatment of liver cancer<\/a><\/h3>Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.<\/summary><\/li>The 'death switch' in sepsis also promotes survival<\/a><\/h3>Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis.<\/summary><\/li>Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
Redesign of US donor-liver network could boost transplants by several hundred per year<\/a><\/h3>A redesign of the nation\u00e2\u20ac\u2122s donor-liver distribution network developed by University of Pittsburgh researchers could result in several hundred more people each year receiving the transplants they need.<\/summary><\/li>Nanotechnology may lead to new treatment of liver cancer<\/a><\/h3>Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.<\/summary><\/li>The 'death switch' in sepsis also promotes survival<\/a><\/h3>Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis.<\/summary><\/li>Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
Nanotechnology may lead to new treatment of liver cancer<\/a><\/h3>Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.<\/summary><\/li>The 'death switch' in sepsis also promotes survival<\/a><\/h3>Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis.<\/summary><\/li>Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
The 'death switch' in sepsis also promotes survival<\/a><\/h3>Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis.<\/summary><\/li>Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
Predicting liver cancer spread<\/a><\/h3>Patients with cancer usually do not die as a result of their originally diagnosed tumor. However, many do so as a result of metastatic disease \u00e2\u20ac\u201d tumors that arise at distant sites after spreading from the original tumor. Identifying biomarkers of tumor metastasis would therefore be of immense clinical benefit.<\/summary><\/li>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li><\/a><\/figure>Cell Transplantation reports a success in treating end-stage liver disease<\/a><\/h3>Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.<\/summary><\/li>People suffering from fatty liver disease may be three times more likely to suffer a stroke<\/a><\/h3>People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.<\/summary><\/li>Metabolic syndrome found in 52 percent of patients after liver transplantation<\/a><\/h3>Researchers from Israel have determined that more than half of liver transplant recipients develop post-transplantation metabolic syndrome (PTMS), placing them at greater risk for cardiovascular disease.<\/summary><\/li>"}
<\/a><\/figure>